31.55
+1.6813(+5.63%)
Currency In USD
| Previous Close | 29.87 |
| Open | 30.55 |
| Day High | 31.75 |
| Day Low | 30.27 |
| 52-Week High | 36.54 |
| 52-Week Low | 12.21 |
| Volume | 446,389 |
| Average Volume | 559,910 |
| Market Cap | 883.31M |
| PE | -7.19 |
| EPS | -4.39 |
| Moving Average 50 Days | 22.68 |
| Moving Average 200 Days | 20.24 |
| Change | 1.68 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $1,855.96 as of October 08, 2025 at a share price of $31.551. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,890.43 as of October 08, 2025 at a share price of $31.551.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
GlobeNewswire Inc.
Sep 29, 2025 8:05 PM GMT
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
GlobeNewswire Inc.
Sep 29, 2025 8:05 PM GMT
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD1
Anaptys Announces Participation in September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 8:15 PM GMT
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o